Adaptimmune Therapeutics/ADAP

$1.71

7.92%
-
1D1W1MYTD1YMAX

About Adaptimmune Therapeutics

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. It develops T-cell therapies for solid tumors and has reported responses in multiple solid tumor indications. Its platform helps to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. Its cell therapy candidates include genetically engineered T-cell receptors (TCRs) and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Its MAGE-A4 cell therapy franchise includes T-cell therapy products targeting solid tumor indications in which the MAGE-A4 antigen is expressed, with responses seen in eight indications (head and neck, esophagogastric junction, non-small cell lung cancer-squamous, synovial sarcoma, melanoma, urothelial, ovarian and myxoid/round cell liposarcoma indications).

Ticker

ADAP

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Adrian Rawcliffe

Employees

534

Headquarters

Abingdon, United Kingdom

ADAP Metrics

BasicAdvanced
$336.14M
Market cap
-
P/E ratio
-$0.49
EPS
2.36
Beta
-
Dividend rate

What the Analysts think about ADAP

Analyst Ratings

Majority rating from 7 analysts.
Hold

Price Targets

Average projection from 6 analysts.
110.53% upside
High $9.00
Low $1.00
$1.71
Current price
$3.60
Average price target

ADAP Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-624.65% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$7.3M
43.14%
Net income
$-45.6M
114.08%
Profit margin
-624.65%
49.57%

ADAP Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 72.41%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.18
$0.01
-$0.12
-$0.20
-
Expected
-$0.25
-$0.15
-$0.13
-$0.12
-$0.10
Surprise
-27.52%
-106.89%
-9.87%
72.41%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

Buy or sell Adaptimmune Therapeutics stock

Buy or sell Adaptimmune Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing